Allogene Therapeutics Cash from Financing (TTM) Insights

Allogene Therapeutics Inc (ALLO)

2.88 +0.02 (+0.88%) USD | NASDAQ | Apr 26, 16:00

2.88 0.00 (0.00%) After-Hours: 17:39

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2018. Upgrade now.

Date	Value
December 31, 2023	95.70M
September 30, 2023	95.59M
June 30, 2023	92.37M
March 31, 2023	2.867M
December 31, 2022	2.95M
September 30, 2022	3.226M
June 30, 2022	4.543M
March 31, 2022	7.733M
December 31, 2021	11.96M
September 30, 2021	24.62M
June 30, 2021	26.09M

Date	Value
March 31, 2021	623.05M
December 31, 2020	633.59M
September 30, 2020	677.09M
June 30, 2020	674.80M
March 31, 2020	74.86M
December 31, 2019	58.96M
September 30, 2019	347.01M
June 30, 2019	619.50M
March 31, 2019	771.87M
December 31, 2018	771.18M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

2.867M

Minimum

Mar 2023

677.09M

Maximum

Sep 2020

214.55M

Average

74.86M

Median

Mar 2020

Cash from Financing (TTM) Benchmarks